CR9993A - Formulación de suspensión de fexofenadina - Google Patents

Formulación de suspensión de fexofenadina

Info

Publication number
CR9993A
CR9993A CR9993A CR9993A CR9993A CR 9993 A CR9993 A CR 9993A CR 9993 A CR9993 A CR 9993A CR 9993 A CR9993 A CR 9993A CR 9993 A CR9993 A CR 9993A
Authority
CR
Costa Rica
Prior art keywords
suspension formulation
fexofenadine
fexofenadine suspension
dihydrate
directed
Prior art date
Application number
CR9993A
Other languages
English (en)
Spanish (es)
Inventor
Agrawala Prafulla
Chrzan Kazimierz
Haribhkti Rajiv
Mermey Matthew
J Porcello Curtis
Lee Silvey Gary
Tran Vinh
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38120312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9993(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of CR9993A publication Critical patent/CR9993A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
CR9993A 2005-12-14 2008-05-20 Formulación de suspensión de fexofenadina CR9993A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75030305P 2005-12-14 2005-12-14

Publications (1)

Publication Number Publication Date
CR9993A true CR9993A (es) 2008-09-23

Family

ID=38120312

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9993A CR9993A (es) 2005-12-14 2008-05-20 Formulación de suspensión de fexofenadina

Country Status (38)

Country Link
US (1) US8933097B2 (https=)
EP (1) EP1965768B1 (https=)
JP (1) JP5308824B2 (https=)
KR (1) KR101452792B1 (https=)
CN (1) CN101316580B (https=)
AR (1) AR058323A1 (https=)
AT (1) ATE431137T1 (https=)
AU (1) AU2006326551B2 (https=)
BR (1) BRPI0619895B1 (https=)
CA (1) CA2633086C (https=)
CR (1) CR9993A (https=)
CY (1) CY1109320T1 (https=)
DE (1) DE602006006870D1 (https=)
DK (1) DK1965768T3 (https=)
DO (1) DOP2006000274A (https=)
EC (1) ECSP088532A (https=)
EG (1) EG25866A (https=)
ES (1) ES2327168T3 (https=)
HN (1) HN2008000875A (https=)
HR (1) HRP20090411T1 (https=)
IL (1) IL192067A (https=)
JO (1) JO2549B1 (https=)
MA (1) MA30152B1 (https=)
MY (1) MY146988A (https=)
NO (1) NO339877B1 (https=)
NZ (1) NZ568943A (https=)
PE (1) PE20071003A1 (https=)
PL (1) PL1965768T3 (https=)
PT (1) PT1965768E (https=)
RS (1) RS51135B (https=)
RU (1) RU2405538C2 (https=)
SI (1) SI1965768T1 (https=)
TN (1) TNSN08186A1 (https=)
TW (1) TWI377061B (https=)
UA (1) UA89584C2 (https=)
UY (1) UY30021A1 (https=)
WO (1) WO2007070517A2 (https=)
ZA (1) ZA200803985B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101546774B1 (ko) 2008-07-29 2015-08-24 엘지전자 주식회사 휴대 단말기 및 그 동작제어 방법
CA2852447A1 (en) 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
US10130620B2 (en) 2013-07-01 2018-11-20 Aventisub Llc Liquid pharmaceutical composition for oral administration comprising fexofenadine
BR112015032791A2 (pt) * 2013-07-03 2017-07-25 Scherer Technologies Llc R P composição para uso como enchimento de cápsula, e, cápsula
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
CN106806346B (zh) * 2015-12-01 2020-09-11 国药集团广东环球制药有限公司 一种非索非那定盐酸盐干混悬剂制剂及其制备方法
ES3014923T3 (en) 2016-06-16 2025-04-28 Azurity Pharmaceuticals Inc Composition and method for proton pump inhibitor suspension
EP3639812A4 (en) 2017-06-02 2021-03-17 Teika Pharmaceutical Co., Ltd. SOLUBILIZED MICELLA CONSISTING OF A LOW SOLUBLE COMPONENT AND SOLUTION CONTAINING IT
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
EP4199980A1 (en) * 2020-08-18 2023-06-28 Innate S.r.l. Injectable composition and use of said composition
WO2022175829A1 (en) 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
AU2021480621A1 (en) * 2021-12-29 2024-07-18 Opella Healthcare Group Sas Compositions containing fexofenadine
CN115715759B (zh) * 2022-11-03 2024-01-12 京海盛达(北京)科技有限公司 一种抗组胺混悬剂及其制备方法
EP4651852A1 (en) 2023-01-20 2025-11-26 Opella Healthcare Group SAS Paraben-free fexofenadine formulations
WO2026074306A1 (en) 2024-10-03 2026-04-09 Opella Healthcare Group Sas Chewable fexofenadine tablets

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
CN1148849A (zh) * 1994-05-18 1997-04-30 赫彻斯特马里恩鲁斯公司 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
WO2003011295A1 (en) 2001-07-31 2003-02-13 Texcontor Etablissement Fexofenadine polymorph
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
CA2514570C (en) * 2003-01-30 2011-09-06 Ethypharm Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
DK2377557T3 (en) * 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
CN101228128A (zh) 2005-07-27 2008-07-23 桑多斯股份公司 一种用于制备取代苯基醚化合物和罗西格列酮的方法
JP5133244B2 (ja) * 2005-08-05 2013-01-30 ルピン・リミテッド フェキソフェナジンの経口用医薬懸濁組成物

Also Published As

Publication number Publication date
PT1965768E (pt) 2009-08-07
PE20071003A1 (es) 2007-10-03
DK1965768T3 (da) 2009-09-07
WO2007070517A2 (en) 2007-06-21
UY30021A1 (es) 2007-07-31
DOP2006000274A (es) 2007-10-15
JP5308824B2 (ja) 2013-10-09
JP2009519935A (ja) 2009-05-21
HN2008000875A (es) 2012-01-30
UA89584C2 (en) 2010-02-10
TW200812581A (en) 2008-03-16
IL192067A0 (en) 2009-02-11
DE602006006870D1 (de) 2009-06-25
NZ568943A (en) 2010-04-30
KR101452792B1 (ko) 2014-10-22
US20080299211A1 (en) 2008-12-04
CA2633086A1 (en) 2007-06-21
ES2327168T3 (es) 2009-10-26
ATE431137T1 (de) 2009-05-15
MY146988A (en) 2012-10-15
RU2405538C2 (ru) 2010-12-10
BRPI0619895B1 (pt) 2022-04-12
SI1965768T1 (sl) 2009-10-31
WO2007070517A3 (en) 2007-08-23
TNSN08186A1 (en) 2009-10-30
CA2633086C (en) 2011-10-18
CN101316580B (zh) 2011-11-16
ZA200803985B (en) 2009-03-25
CN101316580A (zh) 2008-12-03
RS51135B (sr) 2010-10-31
TWI377061B (en) 2012-11-21
ECSP088532A (es) 2008-08-29
IL192067A (en) 2010-12-30
CY1109320T1 (el) 2014-07-02
JO2549B1 (en) 2010-09-05
AU2006326551B2 (en) 2012-06-07
EP1965768A2 (en) 2008-09-10
KR20080074180A (ko) 2008-08-12
US8933097B2 (en) 2015-01-13
RU2008128418A (ru) 2010-01-20
BRPI0619895A2 (pt) 2011-10-25
NO20082904L (no) 2008-09-10
AR058323A1 (es) 2008-01-30
HK1123197A1 (en) 2009-06-12
MA30152B1 (fr) 2009-01-02
HRP20090411T1 (hr) 2010-01-31
PL1965768T3 (pl) 2009-11-30
EG25866A (en) 2012-09-12
AU2006326551A1 (en) 2007-06-21
EP1965768B1 (en) 2009-05-13
NO339877B1 (no) 2017-02-13

Similar Documents

Publication Publication Date Title
CR9993A (es) Formulación de suspensión de fexofenadina
HRP20120323T1 (en) Diarylhydantoin compounds
SG161311A1 (en) Novel use of spiegelmers
ES2531093T3 (es) Procedimiento de preparación de halogenuros de N-alquil-naltrexona
UA105229C2 (uk) Фармацевтичний склад
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
DOP2012000038A (es) Conjugados de dímeros de pirrolo [1,4] benzodiazepina como agentes anticancerosos
GT200600084A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
AR093716A1 (es) Composicion de cuidado oral
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
CY1116840T1 (el) Χρηση 24-norudca
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
ECSP088374A (es) Formulacion de aerosol para inhalacion
AR077915A1 (es) Forma cristalina de pemirolast
JP2011512405A5 (https=)
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
WO2007138462A3 (en) Aqueous oral formulations of risperidone
GT200500031A (es) Procesos para la preparacion de haluros de arilalquilsulfonilo y haluros de heteroarilalquilsulfonilo
NO20082973L (no) Salter av styfninsyre
ATE535230T1 (de) Fosphenytoin-zusammensetzung

Legal Events

Date Code Title Description
FC Refusal